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Dyspnea is a common and distressing symptom associated with multiple chronic illnesses and 
high levels of burden for the individual, their families and health care systems. The subjective 
nature of the dyspnea symptom and a poor understanding of pathophysiological mechanisms 
challenge the clinician in developing management plans. Nebulised furosemide has been 
identified as a novel approach to dyspnea management. This review article summarises 
published studies, both clinical and experimental, reporting the use of nebulised furosemide. 
The search criteria yielded 42 articles published in the period 1988 to 2004. Whilst nebulised 
furosemide appeared to have a positive influence on a person’s dyspnea and physiological 
measurements, caution must be taken with the results primarily coming from small-scale 
clinical trials or observation trials. Despite the limitations of the studies reported, given the 
range of conditions reporting effectiveness of nebulised furosemide, further investigation of 
this potential novel treatment of dyspnea is warranted.   
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The burden of dyspnea in chronic illness 
Dyspnea, the subjective experience of breathlessness(1) and is a common and distressing 
symptom in many chronic illnesses, including both malignant and non-malignant conditions. 
The frequency and intensity of dyspnea can worsen, in both intensity and frequency, as the 
disease progresses or during periods of exacerbation. This symptom burden often remains 
despite optimal therapy.(2) A reduction in self-rated quality of life is also seen with dyspnea, 
due to a reduction in the capacity for physical activity and  the potential for adverse 
psychological symptoms.(1)  
 
In spite of the prevalence of dyspnea, the precise physiological mechanisms remain unclear 
for symptom aetiology and experience. It is important to consider that dyspnea is a 
multidimensional symptom, involving not only physiological mechanisms, but also 
environmental, psychological and social factors. It is the interplay of these multiple factors 
which  are responsible determine the severity and degree of the symptom.(1)  
 
The significant disease burden of dyspnea has led to the exploration of many approaches to 
relieve this distressing symptom.(1) Nebulised furosemide, a common loop diuretic in the 
management of oedematous symptoms, has been tested as a treatment option for dyspnea.(3) 
This treatment option is attractive from both a physiological and management perspective. 
The potential to achieve adjunctive benefits to symptom management such as ancillary 
bronchodilator therapy in asthma, chronic obstructive pulmonary disease (COPD) and 
malignancy is an attractive option as well as the capacity to administer the drug in a non-





The action of furosemide 
Furosemide produces increased diuresis through inhibition of the Na+-K+-2Cl- co-transporter 
in the thick ascending limb of the loop of Henle.(4,5) The reported range of oral availability of 
furosemide is 10-100% with the mean availability being 60%.(5) Approximately 50-65% of 
furosemide is excreted in the urine unchanged.(4,5) The plasma half-life of furosemide is 
approximately 1.5 hours(4,5) in a healthy individual but this figure is nearly double when there 
is renal, hepatic and cardiac deficiencies.(5)  
 
Despite extensive research into the mechanism of action using in vitro models, the precise 
mechanism of action of nebulised furosemide is still unknown leading to speculation that 
more then one mechanism of action is involved.(6,7) Animal and in vitro models suggest that 
the protective effects of nebulised furosemide are unlikely to be by the same mechanism that 
it enacts in the kidneys. These models have suggested several mechanism including its 
protective effect against cholinergic, noncholinergic and nonadreneric contraction of smooth 
muscle,(8-10) producing an increased vascular response to the tissue,(11) enhancing 
microvascular leakage to counteract the evaporation of water(12) and vasodilation.(13,14) Recent 
work in an anesthetised rat model suggested nebulised furosemide could work through the 
activation of pulmonary stretch receptors and inhibition of vagal irritant receptors.(15) The 
failure of oral furosemide to protect against exercise induced asthma compared to the 
protective effect of nebulised furosemide in Bianco’s original study, suggests nebulised 
furosemide has a direct protective effect.(3)  
Methods: 
The electronic data bases, Medline, Embase, and CINAHL, as well as the World Wide Web 
were searched for literature in English using key words which included “dyspnea”, 
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“breathless” “inhaled”, “nebulised”, “furosemide” and “furosemide” from 1988 to 2006. The 
reference lists of published articles were also examined to find additional references. Articles 
were considered suitable if they reported findings of clinical or experimental trials of 
nebulised furosemide for the management of dyspnea in human adults. Both randomized and 
non-randomized controlled trials were included in this review. The heterogeneity of study 
design, populations, and endpoints precluded the formal use of metanalysis techniques. 
Results: 
Initially the search generated 112 citations. In total, 42 articles were retrieved which met the 
inclusion criteria. The articles retrieved included 39 randomised control trials, 35 studies in 
asthma, 2 studies in cancer, 8 in healthy participants, 1 in chronic obstructive pulmonary 
disease, 5 articles measured dyspnea and 40 articles measured changes in physiological 
outcomes. These are summarised in Table 1. A critical review of the articles was undertaken 




Several studies and case reports have reported the use of nebulised furosemide as an 
adjunctive treatment for acute asthma. Two studies reported improvement in pulmonary 
function when nebulised furosemide (20-100mg) was used after or in conjunction with 
standard treatment which included sympathomimetics, aminophylline, and steroids.(16,17) 
These studies showed the addition of nebulised furosemide was able to significantly improve 
FEV1 at 60 minutes,(17) and produce a rapid fall in PaCO2 within 20-60 minutes.(16) When 
compared to salbutamol, nebulised furosemide (100mg) did not increase FEV1 as much as 
salbutamol (6.9% compared to 7.9% respectively) at 10 and 30 minutes, however, this 




In contrast, Pendino and colleagues did not show an overall greater protection from nebulised 
furosemide than normal saline when added to salbutamol (2.5mg). A significant improvement 
in peak expiratory flow rate (PEFR) was seen on post hoc analysis in the nebulised 
furosemide group in those patients that had presented to the emergency room within 8 hours 
of the onset of their symptoms.(19) In a further study, comparing nebulised furosemide with 
salbutamol in subjects who had not received a nebulised beta agonist in the previous 6 hours, 
furosemide failed to show a significant improvement in FEV1. However, the group assigned 
metaproternol alone did have a significant improvement in their FEV1.(20)  
Experimentally Induced Asthma 
Multiple experimental studies have demonstrated the ability to reduce the effects of 
bronchoconstrictive agents. Adenosine 5’-Monophosphate (AMP) induces 
bronchoconstriction through the enhancement of mast cell mediated release(21,22) and 
interference with neural pathways.(22) The protective effects of nebulised furosemide against 
AMP induced bronchoconstriction can last for up to 120 minutes.(23) Ultrasonically nebulised 
distilled water (UNDW) likely induces bronchoconstriction through indirectly causing smooth 
muscle contraction.(24) Nebulised furosemide (28-40 mg) was able to significantly increase the 
amount of UNDW required to reduce FEV1 by 20%.(24-26) Nebulised furosemide (30-40mg) 
successfully increased the amount of sodium metabisulfite (MBS), an indirect stimulant of 
bronchoconstriction required to produce a 20% fall in FEV1. This effect was relatively short, 
with protection lasting between 1.5-3 hours.(27-31)  
 
Bronchoconstriction is directly produced by methacholine through stimulation of muscarinic 
receptors on airway smooth muscle.(21) There have been different results of the ability of 
nebulised furosemide to prevent methacholine-induced bronchoconstriction. Nebulised 
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furosemide (30mg and 28mg) provided no protection against methacholine-induced 
bronchoconstriction in two studies, while one study showed nebulised furosemide (28mg) was 
able to increase the amount of methacholine required to produce a 20% fall in FEV1. 
 
Based upon available data, it is unlikely that nebulised furosemide provides protection against 
bronchoconstriction by the same mechanism as it exerts diuresis in the kidneys. Nebulised 
furosemide has been shown to: (1) provide protection against bronchoconstriction when other 
loop diuretics such as bumetanide, failed to provide protection (2) reduced the amount of 
experimentally induced bronchoconstriction compared to other loop diuretics (bumetanide, 
torasemide) (3) provided the same level of protection against MBS induced 
bronchoconstriction when equivalent doses of ethacrynic acid, a loop diuretic with a different 
mechanism of action was used.(31) 
 
Nebulised furosemide has been shown to be effective against exercise induced asthma.(3,32) In 
Bianco’s original study, nebulised furosemide was able to protect against exercise induced 
asthma but oral furosemide was ineffective. This level of protection was also shown to be 
dose dependent.(3) Furosemide was able to reduce the level of fall of FEV1 as a result of 
exercise from 26% with placebo to 14.3%.(32) Another common cause of asthma is allergens. 
Two studies have examined the efficacy of nebulised furosemide (~28-40mg) to protect 
against allergen-induced asthma with encouraging results. The protective effects have been 
seen immediately,(33) and as late as 4-12 hours.(34)  
 
Nebulised furosemide has also proven effective against isocapnic hyperventilation (13,35) and 
dry air challenges.(36) Gilbert and colleagues found that the protection furosemide provided in 
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the isocapnic hyperventilation challenge was in conjunction with changes in thermal 
gradients.(13)   
 
Aspirin can induce asthma in some patients through the inhibition of cyclooxygenase.(37,38) 
Nebulised furosemide has been shown to provide protection against aspirin induced 
bronchoconstriction in two randomised controlled studies.(37,38) When patients took 
indomethacin, a known inhibitor of cyclooxygenase, (50mg,) three times a day for 3 days 
prior to the test, the effects of nebulised furosemide were significantly reduced.(32) 
Flurbiprofen, a suspected inhibitor of the synthesis and release of prostaglandins has 
demonstrated mixed results with nebulised furosemide. Participants that took flurbiprofen 
50mg twice daily, for 3 days prior to a methacholine challenge showed flurbiprofen was able 
to abolish the effects of nebulised furosemide occurred in both asthmatics and healthy 
subjects.(39) However, a single dose of flurbiprofen (200mg), enhanced the protective effects 
of nebulised furosemide when taken as a single dose 2 hours prior to a sodium metabisulphite 
challenge.(30)  
 
The results from these studies highlight the difficulty of finding the mechanism of action of 
nebulised furosemide. The ability of furosemide to provide protection against a wide of agents 
with many different mechanisms of action suggests that nebulised furosemide may work at 
different sites in the respiratory system. The encouraging results from the few clinical trials of 
furosemide in asthma suggest further examination is warranted.  
 
Cancer 
Two studies have examined the efficacy of nebulised furosemide for the alleviation of 
dyspnea in end stage cancer patients.(40,41) Nebulised furosemide (20mg) three times daily was 
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able to relieve dyspnea, when standard treatments (morphine, oxygen and orciprenaline) were 
no longer effective.(41) Interestingly, another group of patients stated nebulised furosemide 
relieved their dyspnea using the Cancer Dyspnea Scale, particularly in the sense of effort and 
reduced anxiety items, but there was no significant reduction in the objective measures 
including arterial blood gases, SaO2, heart rate and respiratory rate. Whilst these studies were 
of case study design, they provided encouraging results for the use of nebulised furosemide in 
this group of patients and further investigation is warranted.(40)  
Chronic Obstructive Pulmonary Disease (COPD) 
In a study by Ong and co-workers, participants with moderate or severe COPD had dyspnea 
induced with exercise following administration of either nebulised furosemide or nebulised 
normal saline in a controlled clinical trial. There was a significant improvement in the patients 
FEV1 after nebulised furosemide. The patient’s perception of their dyspnea, as measured by a 
visual analogue scale (VAS), also significantly improved following nebulised furosemide. No 
significant difference was found with incremental exercise testing.(42)  
Healthy subjects 
Ventresca et al reported on nebulised furosemide’s ability to protect against induced cough in 
healthy participants.(43) In this study, nebulised furosemide was unable to protect against 
capsaicin induced cough although it did protect against prostaglandin F2α induced cough. 
 
It is unlikely that nebulised furosemide prevents dyspnea through a decrease of the ventilatory 
drive of CO2.(44) Whist nebulised furosemide was able to protect against breath holding and a 
combination of resistive flow loading and hypercapnia induced bronchoconstriction,(45) there 





As was the case with asthmatic subjects,(21) nebulised furosemide was able to protect against 
methacholine induced bronchoconstriction.(39) The loop diuretic bumetanide was also 
successful in protecting against methacholine induced bronchoconstriction in this study.  
Reported adverse events 
Although the therapeutic effects of nebulised furosemide are attractive, it is important to 
consider potentials for adverse effects, particularly within the context of polypharmacy and 
co-morbid conditions.  
Increased diuresis 
Inconsistencies are reported regarding increased diuresis following inhalation of nebulised 
furosemide. Increased diuresis has only been reported in 4 studies in adults.(18,29,43,46) The 
effect of the increased diuresis has been reported to last for up to 24 hours.(29) There was a 
non statistically significant increase in diuresis in the study from Rodriguez et al(18) in the 
furosemide group compared to placebo. Increased diuresis was reported in 1 of 8 participants 
in the study from Ventresca et al.(43) Ten studies either specifically reported that there was no 
increase in diuresis or that no adverse events had occurred following inhalation of nebulised 
furosemide.(3,16,20,25,27,31,33,40,41,47) No reference to adverse events was made in the remaining 
articles reviewed.  
Discussion 
 
There is some evidence to suggest nebulised furosemide could be an option to use in the 
management of dyspnea. The case reports of the improvement in dyspnea scores in cancer 
patients are encouraging; especially given the fact the more traditional dyspnea strategies of 
opioids were not effective in these patients. Yet in the absence of adequately powered, 
randomised controlled clinical trials these observations need to be interpreted with 




There is further need for studies to evaluate the efficacy of nebulised furosemide on dyspnea 
management. The majority of studies reported in this review report the effects of nebulised 
furosemide on pulmonary function and asthma. Whilst there may be some correlation 
between pulmonary function and dyspnea scores such as lung cancer, there is need to use 
reliable and valid dyspnea measurement scales with nebulised furosemide use.  
 
The lack of data in the reports surrounding possible diuretic effects of nebulised furosemide is 
worrisome given the fact that furosemide is a loop diuretic. There is a clear need for 
pharmacological studies to answer this question if nebulised furosemide is to be used 
routinely in clinical practice. There is also the potential if nebulised furosemide does have a 
diuretic effect that this may identify a potential useful vehicle of administration. Both animal 
and human studies have identified several possible mechanisms for the action of nebulised 
furosemide including enhanced pulmonary receptor activity, suppression of the pulmonary 
irritant activity and vasodilation. The complexity of management regimes of the likely 
populations of nebulised furosemide also demands that the pharmacology be determined so 
safe, effective prescription is possible. 
Limitations of this review 
This review has summarised published data to inform future studies and demonstrate potential 
pharmacological strategies to facilitate symptom management. Therefore only clinical trials of 
nebulised furosemide in adult humans for the management of dyspnea were reviewed for this 
manuscript. The heterogeneity of study samples, dosages and methods precludes making firm 




This review of nebulised furosemide for managing dyspnea is limited by the lack of studies 
which measured dyspnea and the heterogeneity of populations and study methods precluding 
metanalysis technique. Dyspnea was only evaluated in 5 papers.(40-42,44,45) The lack of 
assessment of dyspnea in the papers is a limitation across many of the studies particularly 
since there is not always a strong correlation between disease severity and symptom 
burden.(1,48) Yet  the symptom relief of nebulised furosemide in the studies using validated 
measures of assessing dyspnea suggest nebulised furosemide should continued to be 
evaluated.(40-42,44,45)  
Conclusion 
The pathophysiological basis of dyspnea is still not fully understood, limiting appraisal of the 
mechanistic effects of published studies of nebulised furosemide. Dyspnea research is also 
problematic due to the subjectivity of this sensation and the complex interplay between 
physiological and psychological responses that can influence the sensation and manifestation 
of this symptom. While several studies have examined the effect of nebulised furosemide for 
the management of dyspnea, methodological limitations make it difficult to derive 
conclusions regarding efficacy and therapeutic action. Further studies to examine efficacy, 
indications, and safety profile are necessary before this treatment strategy can be 
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N/A Saline 40 Study intervention 
added to 2.5mg 
nebulised salbutamol 








Either 40mg of furosemide or saline 
was added to 2.5mg salbutamol 
No difference in PEFR† at 15 or 30 


























Salbutamol group (FEV1‡ improved 
7.9% at 10 min and 30 min, furosemide 












N/A Saline 20 All patients received 
IV aminophylline 
250 mg for 90 min 
and IV 
hydrocortisone 100 







Significant increase in mean FEV1 in 













N/A N/A 20 Patients unresponsive 











Rapid mean fall in PaCO2 from 57.7 
mmHg (46.2-66.3 mmHg) to 40.6 
mmHg (37.5-46.5 mmHg) within 20-
60 minutes. 
                                                 
* Randomised control trial 
† Peak expiratory flow rate 

























40 Patients in the 
emergency 














Furosemide alone resulted in 
14.9±10.5% improvement in FEV1 
which was not significant and was less 
then metaproterenol alone 29.2±15.2% 
which was significant (p=0.0028) 
No additional improvement with 


















33.2 Patients had dose of 
4.5% NaCl required 
to decrease FEV1 by 
20%. Patients 
returned at least 3 
days later and 
repeated procedure 
10 minutes after 







The amount of 4.5% NaCl required to 
produce a 20% fall in FEV1 was 1.3ml 
(95% CI 0.7-2.3) with placebo and 8.2 
(95% CI 4.7-14.1) with furosemide 
Increased FEV1 from baseline after 
4.5% NaCl with exposure to 















~28 Amount of allergen 
required to decrease 
FEV1 recorded. On 
second and third 
















Mean maximal fall in FEV1 with 
placebo and furosemide was (31.5%; 
95%CI 40.2%-22.8% vs 8.4%; 1 1.8%-
4.9%) 
Furosemide provided protection from 
immediate reaction to inhaled allergen 
                                                 
















40 Amount of allergen 
required to decrease 
FEV1 recorded on 
first visit. On second 








Mean maximal fall in FEV1 after 60 
min was 35±4% with placebo and 
11±2% with furosemide (p<0.05) 
Mean maximal fall in FEV1 between  
4-12 hrs was 35±5% with placebo and 
























40 Study 1:Amount of 
allergen required to 
decrease FEV1 
recorded. On second 
and third visit, same 
dose administered 
after study solution. 
Study 2: Time course 
analysis of bronchial 








Increased AMP concentration required 
to decrease FEV1 by 20% from 21.2 
mg/ml (2.5-96.9 mg/ml) to 83.4 mg/ml 
(11.3-345.0 mg/ml; p<0.01) after 
furosemide and 33.8 (4.7-120.9 mg/ml; 
p<0.05) 





















underwent a series of 
bronchial challenges 








Furosemide attenuated the effects of 
AMP (log PC20 1.59± 0.24) compared 
with placebo log PC20 0.98± 0.28, 
p<0.01) 
No response was seen from furosemide 
following inhalation of histamine (log 
PC20 0.09± 0.17) or placebo (log PC20 
















40 Following baseline 








Mean maximal fall in FEV1 following 
AMP was 14.86 (2.6-104.6) after 
placebo and 80.97 (9.97->400.0 mg/ml 
                                                 




al(22) kinin  
 
o participants were 
then given study 




Mean maximal fall in FEV1 following 
bradykinin was 2.52 (0.45-5.61) after 
placebo and 13.22 (2.53->16.0) mg/ml 
after furosemide 
Furosemide provided 5.45 and 5.24 

























in phase 1. Phase 2 
Study solution given 
5 minutes prior to 
repeat challenge on 







Increased dose required for a 20% fall 
in FEV1 with AMP from 30 to 96 mg 
ml-1 (p<0.01) 
Increased dose required for a  20% fall 
in FEV1 with methacholine from 1.1 to 
1.8 mg ml-1 (p<0.01) 
Furosemide provided significantly 
greater protection to AMP induced 





















study solution  
Phase 2. The dose of 
aspiring was 
delivered in 







Furosemide provided significant 
protection against a single aspirin 
challenge for 120 minutes. 
Furosemide provided significant 
protection in the first 90 minutes when 
multiple doses of aspirin were 
















38 Phase 1: Baseline 
challenge. 
Phase 2: Study 
solution inhaled 10 







The mean difference in PVE20 between 
amiloride and furosemide was 21.5 l-



















40 Took indomethacin 
or placebo for 3 
times a day for 2 
days prior to exercise 
test.  
10 minutes before 








The mean maximal fall in FEV1 from 
baseline following furosemide prior to 
exercise challenge was 14.3% 
compared to 26% with placebo 
(p<0.01).  
Three days pre-treatment with 
indomethacin increased the mean 
maximal fall to 21.8% in the 
furosemide group, mean difference 
























Study 1: Participants 
inhaled study 
solution before 
exercise test.  
Study 2: Study 1 
protocol repeated 
except additional day 
for extra dose. 
Study 3. Compared  
different combination 










Mean maximal fall in FEV1 was 33.8% 
(39.1-28.5) with placebo and 11.5% 
(14.3-8.7) with furosemide 
The protection is dose-dependent and 
was not accompanied by any direct 
bronchodilator effect.   

























The geometric mean (histamine PD20) 
after inhalation of the solution was 
0.6µmumol and after furosemide was 
0.45µmumol.  
The mean difference in PD20 between 
                                                 
‡‡ Blood pressure 
§§ Heart rate 
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control and furosemide was -0.50 µmol 
(furosemide test more reactive) but this 


















Phase 1: Participants 
inahled frigid air at 
baseline. 
Phase 2: Protocol 
repeated after study 








Mean maximal fall in FEV1 occurred 
after 10 minutes in both groups.  
Significantly greater decrement in lung 
function after saline compared to 
furosemide up to 45 minutes 
(p<0.006). FEV1 returned to baseline 
after 45 minutes with saline and 30 
minutes with furosemide. 
Furosemide significantly attenuated 
airstream cooling at 3 (p<0.04) and 4 
minutes (p<0.01) and absolute end-
inspiratory airstream temperature was 
warmer in furosemide then saline 













Saline 20 Participants inhaled 
saline on day 1 and 
furosemide on day 2. 
Following inhalation 
patients underwent 








Mean dose causing 20% fall in FEV1 
with placebo was 30.4 mg/ml 
None of the participants FEV1 fell by 
20% when pre-treated with furosemide 















study solutions on 
separate day s,10 








Compared furosemide, ethacrynic acid 
and placebo (saline) 
Furosemide (20 and 40mg) increased 
the amount of UNDW*** required to 
                                                 
*** Ultrasonically nebulised distilled water 
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acid undergoing MBS 














produce a 20% fall in FEV1 (mean 1.1; 
95CI;0.-2.4; p>0.05) and (mean1.6;0.4-
2.9;p<0.05) doubling doses 
respectively 
Ethacrynic acid (25 and 50mg) 
increased the amount of UNDW 
required to produce a 20% fall in FEV1 
(0.9;-0.4-2.2;p>0.05) and (1.5;0.2-

















underwent a series of 
bronchial challenges 
with MBS over 4 







Furosemide shifted response curve to 
right by 1.9 (p<0.01) doubling doses 
immediately and 0.7 doubling doses at 
3 hours (p<0.05) 
Furosemide and flurbiprofen (200 mg) 
shifted response curve to right by 2.7 
(p<0.001) doubling doses immediately 
and 1.9 doubling doses at 3 hours 
(p<0.001). Significantly greater then 











MBS Saline 40 Study 1. Baseline 
MBS challenge 
performed 1 hour 
prior to inhalation of 
test solution. MBS 
challenge repeated at 
5 minutes, 1.5, 3, 6 
and 24 hours. 













Furosemide caused a 3.8 fold (95% CI 
2.3-6.3) piretanide 2.5 (1.8-3.4) and 
placebo 1.7 (1.5-1.9) increase in 
PC20MBS. Furosemide and piretanide 
significantly greater then placebo. 
2nd Study: No significant difference in 





90 minutes after 


































Study 1: Inhaled 10 
or 20mg furosemide 
15 minutes before 
MBS bronchial 
challenge.  
Study 2: 2 week run 
in phase then 
participants inhaled 
study solution  4 
times a day for 4 



















Experiment 1: After inhalation of 
furosemide (10mg or 20mg, mean log 
PC20 increased significantly (0.89 ± 
0.08; p<0.02 and 1.10 ± 0.09; p<0.001) 
respectively. 
Experiment 2: No significant 
difference between placebo and 
furosemide when compared to 
baseline, however there was a 
significant difference between 














Saline 30 MBS challenge. 
After determining 
dose of MBS 
required to decrease 
FEV1 by 20% over 3 
test days, subjects 
inhaled test solution.  
Methacholine 
challenge. Repeated 










The level of MBS required to cause 
20% fall in FEV1 were 15.1 mg/ml 
±1.6 after placebo and 40.7 mg/ml ± 

















Furosemide and placebo given every 






by nebulised placebo 












s   
FEV1 improved 15.22% in salbutamol 
group and 12.7% in the furosemide 
group (p>0.05). 
Peak flow in the evening showed no 








N/A Saline 40 Chronic asthma 
patients on high dose 
beclomethasone 
(2mg/day) took a 
combination of 
furosemide (40mg) 
and lysine aspirin 
(720mg) twice daily. 
Steroid dose was 











During placebo phase, all subjects had 
worsening of symptoms 
During combination phase, 2 subjects 
ceased steroid completely, all other 
subjects reduced steroid to 0.5-
0.25mg/day. Mean reduction 71%±7% 
FEV1, weekly PEFR, symptom score 
and bronchodilator were significantly 












Saline 40 Phase 1. Undertook 
concentration 
response studies. 
Phase 2. Test 
solution given 10 
minutes prior to 








Increased the amount of NKA required 
to produce a 20% fall in FEV1 from 
130.3 (35.8-378.8) after placebo to 
419.9(126.5-1000) µg/ml after 
furosemide 
Small increase in the amount of 
histamine required to produce a 20% 
fall in FEV1 from 0.58(0.12-3.80) after 
placebo and 1.04(0.28-4.33) after 
                                                 



















40 All subjects 
underwent 2 
bronchial challenges 












Pre-treatment with furosemide did not 
abolish PAF induced systemic effects, 
or cellular and lung function. 
Furosemide did inhibit the urinary 



















28 Baseline response to 
UNDW challenge.  
3 minutes after 

















Mean dose causing 20% fall in FEV1 
with placebo was 1.73 ml/min, with 
furosemide 4.25 ml/min (p<0.025), and 












Saline 40 Baseline FEV1 
measured before, 5, 
15, 30 min after 
UNDW challenge. 
Procedure repeated 
day 2 and 3 after 








bronchoconstriction in 9 participants 
7.5% decrease in FEV1 following 
furosemide after UNDW compared 
with 31.1% with placebo (p<0.001) 
Maximal increase in NCA§§§ after 
UNDW with placebo was 52.9%, SEM 
                                                 
‡‡‡ Platelet activating factor 
§§§ Neutrophil chemotactic activity 
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Mean maximal fall in FEV1 was 26% 
(20-32) with placebo and 6% (-1-12) 



























with dry air 
challenge. 













Furosemide delayed the onset of 
mucociliary clearance for 
approximately 10 minutes in the whole 
right lung (p<0.002) and central lung 














MBS Saline 40 MBS challenge 
carried out 10 
minutes after 








Compared the effects of nebulised 
furosemide, ipratropium bromide and 
saline against MBS challenge 
Furosemide (p<0.005) and Ipratropium 
bromide (p<0.05) significantly 
inhibited MBS induced 
bronchoconstriction compared to 
placebo but the response was more 









N/A N/A 40 Study solution 





Furosemide had no effect on lung 
mucociliary clearance in asthmatics 
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40 Baseline cough 
challenge performed. 
2 hours later, study 
solution inhaled 
followed by repeat 
cough challenge at 







Furosemide caused a sustained 
inhibition of cough in normal subjects 
(p<0.05 at 2hr, p<0.01 at 4hr) but only 
small, not significant effect at 30min 
with asthma participants 
No significant fall in FEV1 in asthma 
group from chloride deficient solution 














N/A N/A 20 Assessment occurred 



























CDS scores were significantly 
decreased (p=0.007) in 12/15 patients 
with the biggest reduction in sense of 
effort (p=0.013) and reduced anxiety 
(p=0.04) 
No significant changes were observed 
in PaO2, PaCO2, SpO2, HR, RR**** 
                                                 


















N/A N/A 20 Furosemide was 















Nebulised furosemide provided these 
three patients with effective relief of 
their dyspnea in the end stages of their 
disease.  
No titration from the original 20mg 












Saline 40 Study solution 
inhaled followed by 
incremental exercise 
testing. 1 hour later 
another dose of study 
solution followed by 
constant work 
















Significant improvement in mean FEV1 
and FVC‡‡‡‡ following furosemide 
(p=0.038 and 0.005) but not placebo 
Mean VAS§§§§ lower after furosemide 
but not placebo (33.7±25.2 vs 42.4 ± 
24.0 mm, p=0.014) 
Significant bronchodilation after  









CO2 Saline 40 Following CO2 





Inhaled furosemide doesn’t effect 
breathing patterns of resting breathing 
                                                 
†††† Chronic obstructive pulmonary disease 
‡‡‡‡ Forced vital capacity 
§§§§ Visual Analogue Scale 
 
30 
al(44) subjects inhaled 
study solution 











d Inhaled furosemide does not affect the 
slope and intercept of the CO2 response 
curve.  
Inhaled furosemide improves the 





























40 Subjects breathed 
100% O2 for 5 mins. 
Breath held for as 
long as possible. 5 
mins later loaded 
breathholding test 
performed for 7 
minutes. 15 mins 















Total breathholding time after 
furosemide (median 93[78-112]sec) 
and placebo (67 [47-74] sec) p<0.05 
Respiratory discomfort with loaded 




















Saline 30 Study 1 part 1. Study 
solution inhaled 
immediately prior to 
low chloride 
challenge.  




















Chloride free solutions induced 13.1± 
1.6 coughs after placebo and 8.4 ± 1.9 
coughs after furosemide (p<0.005) 
Capsaicin induced 20.8± 1.8 coughs 
after placebo and 21.5 ± 2.7 coughs 




Study 2. Capsaicin 
challenge performed 
after inhalation of 


























Phase 2 and 3. 
Subjects took 3 days 
of flurbiprofen twice 
daily. or placebo. 10 
minutes before 
challenge subjects 







Both by furosemide and bumetanide 
inhibited methacholine-induced 
bronchoconstriction 
The protective effect of furosemide is 
reversed by cyclo-oxygenase blockade 
 
 
